Market Cap | 749.32K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -15.27k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 13.00% |
Sales | 10.21k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -7.00% |
Dividend | N/A | Price/Book | EPS next 5Y | - | 52W High Chg | -75.00% | |
Recommedations | - | Quick Ratio | 0.04 | Shares Outstanding | 37.96M | 52W Low Chg | 186.00% |
Insider Own | - | ROA | - | Shares Float | - | Beta | 10.57 |
Inst Own | 0.00% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.37 |
Gross Margin | 100.00% | Profit Margin | 1,821.37% | Avg. Volume | 114,370 | Target Price | - |
Oper. Margin | -74.97% | Earnings Date | - | Volume | 13,516 | Change | 4.03% |
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.